Rosenqvist E, Høiby E A, Wedege E, Kusecek B, Achtman M
Department of Vaccine, National Institute of Public Health, Oslo, Norway.
J Infect Dis. 1993 May;167(5):1065-73. doi: 10.1093/infdis/167.5.1065.
The 5C protein is expressed by the strain of Neisseria meningitidis (44/76) used for production of the Norwegian meningococcal group B outer membrane vesicle vaccine and is included in the final formulation of this vaccine. The immunoglobulin G antibody response to 5C stimulated by vaccination, systemic meningococcal disease, and carriage was measured using ELISAs with synthetic liposomes as antigen and by immunoblotting. Increased levels of IgG were found in paired sera from all three groups. The antibodies were bactericidal to meningococci of serogroups A and B that expressed large amounts of 5C but not to meningococci expressing smaller amounts. There was a linear correlation between bactericidal titer and units of IgG to 5C.
5C蛋白由用于生产挪威B群脑膜炎球菌外膜囊泡疫苗的脑膜炎奈瑟菌菌株(44/76)表达,并包含在该疫苗的最终配方中。使用以合成脂质体为抗原的酶联免疫吸附测定(ELISA)和免疫印迹法,测定了接种疫苗、全身性脑膜炎球菌病和带菌状态刺激产生的针对5C的免疫球蛋白G抗体反应。在所有三组的配对血清中均发现免疫球蛋白G水平升高。这些抗体对表达大量5C的A群和B群脑膜炎球菌具有杀菌作用,但对表达量较少的脑膜炎球菌则无杀菌作用。杀菌效价与针对5C的免疫球蛋白G单位之间存在线性相关性。